Study: NCT05527795

Intervention type: OTHER
Intervention: Frequency and duration of response to adjuvant immunotherapy according to clinical features
Description: * Frequency of relapse to adjuvant immunotherapy according to clinical features~* Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features

Intervention type: OTHER
Intervention: Frequency and duration of response to adjuvant immunotherapy according to clinical features
Description: * Frequency of relapse to adjuvant immunotherapy according to clinical features~* Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features

Intervention type: OTHER
Intervention: Frequency and duration of response to adjuvant immunotherapy according to clinical features
Description: * Frequency of relapse to adjuvant immunotherapy according to clinical features~* Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features

Intervention type: OTHER
Intervention: Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features
Description: Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features

Intervention type: OTHER
Intervention: Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features
Description: Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features

Intervention type: OTHER
Intervention: Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features
Description: Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features

Intervention type: OTHER
Intervention: Duration of relapse-free survival according to clinical features
Description: Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.

Intervention type: OTHER
Intervention: Duration of relapse-free survival according to clinical features
Description: Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.

Intervention type: OTHER
Intervention: Duration of relapse-free survival according to clinical features
Description: Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.

Intervention type: OTHER
Intervention: Duration of overall survival according to clinical features
Description: Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.

Intervention type: OTHER
Intervention: Duration of overall survival according to clinical features
Description: Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.

Intervention type: OTHER
Intervention: Duration of overall survival according to clinical features
Description: Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.

Intervention type: OTHER
Intervention: Overall response rate
Description: Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.

Intervention type: OTHER
Intervention: Overall response rate
Description: Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.

Intervention type: OTHER
Intervention: Overall response rate
Description: Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.

Intervention type: OTHER
Intervention: Frequency of adverse events according to clinical features
Description: Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features

Intervention type: OTHER
Intervention: Frequency of adverse events according to clinical features
Description: Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features

Intervention type: OTHER
Intervention: Frequency of adverse events according to clinical features
Description: Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features